137 related articles for article (PubMed ID: 38148793)
1. Clinical efficacy of Camrelizumab combined with first-line chemotherapy in extensive-stage small-cell lung cancer.
Zhang D; Kong F; Gao F; Li L; Liang Y; Yu M; Zhao L; Wang N; Jia Y
Heliyon; 2024 Jan; 10(1):e22913. PubMed ID: 38148793
[TBL] [Abstract][Full Text] [Related]
2. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial.
Ni J; Si X; Wang H; Zhang X; Zhang L
Front Immunol; 2023; 14():1168879. PubMed ID: 37114054
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer.
Xu M; Meng X; Lu Y; Wang F
J Gastrointest Oncol; 2022 Apr; 13(2):548-558. PubMed ID: 35557572
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
Xiang J; Gong W; Sun P; Wang X; Liu A
J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
[TBL] [Abstract][Full Text] [Related]
7. Risk of reactive cutaneous capillary endothelial proliferation induced by camrelizumab in patients with non-small cell lung cancer: a retrospective study.
He X; Fang J; Yu P; Hu W; Zhang Q; Zhang Z; Zhou M; Wang X; Bian X
J Thorac Dis; 2023 Dec; 15(12):6687-6696. PubMed ID: 38249866
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety comparison of PD-1 inhibitors
Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
10. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
13. Camrelizumab as a novel third or post-third-line treatment strategy in small cell lung cancer: a retrospective study of 12 patients.
Tian J; Sui L; Wang H; Chen X
Front Oncol; 2023; 13():1180735. PubMed ID: 37469402
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
Front Oncol; 2022; 12():894835. PubMed ID: 36203439
[TBL] [Abstract][Full Text] [Related]
15. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Ding Q; Liu Y; Ju H; Song H; Xiao Y; Liu X; Ren G; Wei D
Med Oral Patol Oral Cir Bucal; 2023 Nov; 28(6):e525-e529. PubMed ID: 37330963
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV).
Xu CR; Chen Q; Zhou C; Wu L; Li W; Zhang H; Li Y; Xu F; Xiong J; Wang Q; Zhang H; Jiang Y; Yin H; Wu Q; Dai Q; Hu J; Chen J; Zhang J; Wu G; Yin J; Zhao J; Liu B; Shan J; Sheng L; Chen Q; Han Z; Shi H; Liu Y; Chen J; Wu YL
Transl Lung Cancer Res; 2023 Jan; 12(1):127-140. PubMed ID: 36762057
[TBL] [Abstract][Full Text] [Related]
17. Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: a prospective multicenter cohort study (NOAH-LC-101).
Wang R; Shi M; Ji M; Han Z; Chen L; Liu Y; Lu K; Liu L; Chen B; Zhang X; Miao L; Shu Y
Transl Lung Cancer Res; 2023 Apr; 12(4):786-796. PubMed ID: 37197631
[TBL] [Abstract][Full Text] [Related]
18. Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer.
Huang Y; Wang J; Hu Y; Cao P; Wang G; Cai H; Wang M; Yang X; Wei Z; Ye X
Front Oncol; 2022; 12():938827. PubMed ID: 36091128
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
20. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
